Monitoring and controlling drug precursors
This procedure is an ordinary-legislation regulation on monitoring and controlling drug precursors. The amendments create a new category for designer precursors, require operators and online marketplaces to report suspicious transactions, thefts and disappearances, set up notification, licensing and a centralised electronic system checked before market access, and cover pre-export objections, customs and cross-border enforcement, penalties, a role for the drugs agency and a safeguard clause for emerging substances.
Procedure timeline
- Committee amendments tabled23 Jun 2026 – 24 Jun 2026
- In progress — not yet concluded
How groups usually vote on similar files
Based on 2,422 past all main roll-call votes, Jul 2019 → 2026-07-25.
If every group voted at its historical rate, with today’s seats: ≈76% of expressed votes in favour.
Seat-weighted baseline over 711 of 711 seats · how often this method is right →
Statistical baseline from past roll-call votes; not a forecast. · roll-call votes only
Follow this procedure — subscribe to its votes (RSS)
Official amendment documents
Connections
See these connections as a navigable graph — and walk from there to anything else.
Explore the graphMembers who amended this procedure
15 Members · by amendment count
The amendments, in full text
285 amendmentsEvery amendment as tabled — original text, proposed change and justification, with a link to the official PDF.